| 2025-12-03 | +299.0% | legal | Seeking Alpha | Capricor Therapeutics: Shares Soaring After DMD Study Win - Ball Now In FDA's Court |
| 2025-12-03 | +299.0% | legal | SEC EDGAR | CAPR 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-12-03 | +299.0% | news | Yahoo Finance | Capricor Therapeutics (CAPR) Valuation After Positive Phase 3 HOPE-3 Results for DMD Therapy Deramiocel - Yahoo Finance |
| 2025-12-03 | +299.0% | news | Quiver Quantitative | Capricor Therapeutics Stock (CAPR) Opinions on HOPE-3 Trial Results - Quiver Quantitative |
| 2025-12-03 | +299.0% | news | Investing.com | Capricor stock soars after DMD therapy meets Phase 3 trial endpoints - Investing.com |
| 2025-12-03 | +299.0% | analyst | Investing.com | Capricor Therapeutics stock price target raised to $51 from $29 at Jones Trading - Investing.com |
| 2025-12-03 | +299.0% | legal | Seeking Alpha | Capricor Therapeutics: Shares Soaring After DMD Study Win - Ball Now In FDA's Court (CAPR) - Seeking Alpha |
| 2025-12-03 | +299.0% | analyst | Investing.com | Capricor Therapeutics stock price target raised to $60 from $24 at H.C. Wainwright - Investing.com |
| 2025-12-03 | +299.0% | news | Investor's Business Daily | Biotech Catapults 535% On Its Sorely Needed Vindication - Investor's Business Daily |
| 2025-12-03 | +299.0% | news | Stock Titan | Capricor Therapeutics (NASDAQ: CAPR) Phase 3 HOPE-3 Meets Skeletal, Cardiac Goals in DMD - Stock Titan |
| 2025-12-03 | +299.0% | news | Benzinga | Why Capricor Stock Is Trading Higher Today - Capricor Therapeutics (NASDAQ:CAPR) - Benzinga |
| 2025-12-03 | +299.0% | analyst | Investing.com | B.Riley reiterates Buy rating on Capricor Therapeutics stock after positive Phase 3 data - Investing.com |
| 2025-12-03 | +299.0% | news | TipRanks | Here’s Why Capricor Therapeutics Stock (CAPR) Took Off Today - TipRanks |
| 2023-09-29 | -48.7% | legal | SEC EDGAR | CAPR 8-K: 1.01, 7.01 (SEC Filing) |
| 2023-09-29 | -48.7% | legal | SEC EDGAR | CAPR 8-K: 7.01, 8.01 (SEC Filing) |
| 2023-08-07 | +24.9% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2025-03-19 | +22.9% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2025-11-24 | -22.4% | news | Investing.com | Capricor Therapeutics stock tumbles after Martin Shkreli short call - Investing.com |
| 2025-11-24 | -22.4% | news | Stocktwits | ‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17% - Stocktwits |
| 2025-12-01 | +19.2% | news | Stocktwits | Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail ‘Best Data’ Ahead Of DMD Data Readout - Stocktwits |
| 2026-03-06 | +19.1% | news | DirectorsTalk Interviews | Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Eyeing a 96.75% Potential Upside in Biotechnology - DirectorsTalk Interviews |
| 2026-03-09 | +19.0% | legal | Seeking Alpha | Biotech firm stocks rise on FDA vaccine heads exit |
| 2026-03-09 | +19.0% | news | Stock Titan | Rare disease biotech Capricor to detail 2025 results Mar. 12 - Stock Titan |
| 2024-09-17 | +16.4% | legal | SEC EDGAR | CAPR 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2024-01-11 | -15.4% | legal | SEC EDGAR | CAPR 8-K: 8.01 (SEC Filing) |
| 2025-11-26 | +15.1% | news | Stocktwits | Why Did Capricor Therapeutics Stock Skyrocket Today? - Stocktwits |
| 2024-10-16 | -14.8% | legal | SEC EDGAR | CAPR 8-K: 2.02 and 8.01 (SEC Filing) |
| 2022-01-25 | +14.5% | legal | SEC EDGAR | CAPR 8-K: 1.01 and (SEC Filing) |
| 2025-09-25 | +14.4% | news | Seeking Alpha | Capricor Therapeutics, Inc. (CAPR) DMD Program Update Call (Transcript) |
| 2025-09-25 | +14.4% | legal | Seeking Alpha | Capricor gains as FDA mulls regulatory flexibility for lead asset |
| 2025-11-07 | -13.1% | earnings | Seeking Alpha | Capricor Therapeutics, Inc. Q3 2025 Earnings Preview |
| 2025-12-05 | +12.6% | news | Seeking Alpha | Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy - Slideshow |
| 2025-12-05 | +12.6% | news | Seeking Alpha | Capricor Therapeutics prices $150M stock offering |
| 2025-12-05 | +12.6% | legal | SEC EDGAR | CAPR 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-12-05 | +12.6% | news | Yahoo Finance | CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know - Yahoo Finance |
| 2025-12-05 | +12.6% | news | Yahoo Finance | Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock - Yahoo Finance |
| 2025-12-05 | +12.6% | news | Stock Titan | Capricor Therapeutics (NASDAQ: CAPR) prices 6M-share offering at $25, targeting $150M - Stock Titan |
| 2022-08-10 | +12.4% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2025-08-11 | -12.2% | earnings | Seeking Alpha | Capricor Therapeutics, Inc. GAAP EPS of -$0.57 misses by $0.10 |
| 2025-08-11 | -12.2% | legal | Seeking Alpha | Biotech sector slips amid reported return of ousted FDA official |
| 2025-08-11 | -12.2% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2025-01-02 | +12.1% | legal | SEC EDGAR | CAPR 8-K: 8.01 and (SEC Filing) |
| 2024-10-09 | -11.8% | legal | SEC EDGAR | CAPR 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-03-05 | +11.3% | news | Stocktwits | Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits |
| 2026-03-05 | +11.3% | news | Stocktwits | CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains - Stocktwits |
| 2023-11-14 | +10.9% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2021-09-24 | -10.6% | legal | SEC EDGAR | CAPR 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-10-10 | -10.6% | legal | Yahoo Finance | Capricor Therapeutics (CAPR): Evaluating Valuation After Lawsuit and FDA Decision Shake Investor Confidence - Yahoo Finance |
| 2023-02-16 | +10.6% | legal | SEC EDGAR | CAPR 8-K: 1.01 and (SEC Filing) |
| 2025-12-04 | -10.5% | expansion | Seeking Alpha | Capricor Therapeutics launches proposed public offering of common stock |
| 2025-12-04 | -10.5% | news | Clinical Trials Arena | Capricor stock soars after pivotal DMD cell therapy trial meets endpoints - Clinical Trials Arena |
| 2025-12-04 | -10.5% | news | Quiver Quantitative | Capricor Therapeutics Announces Proposed Public Offering of Common Stock - Quiver Quantitative |
| 2025-12-04 | -10.5% | news | bitget.com | CAPR Stock Price Prediction: Will CAPR Stock Price Hold Its 500% Surge? - bitget.com |
| 2025-12-04 | -10.5% | news | GlobeNewswire | Capricor Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire |
| 2025-12-04 | -10.5% | news | Stock Titan | Capricor Therapeutics (NASDAQ: CAPR) plans stock offering to fund product development - Stock Titan |
| 2025-12-04 | -10.5% | expansion | Investing.com | Capricor Therapeutics launches common stock offering - Investing.com |
| 2025-11-25 | +10.2% | news | Yahoo Finance | Can Capricor Therapeutics' (CAPR) Exosome Advancement Shift the Conversation on Its Innovation Pipeline? - Yahoo Finance |
| 2022-11-10 | -9.9% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2026-03-10 | +9.9% | legal | Seeking Alpha | Capricor extends rally as FDA to review rejected cell therapy |
| 2026-03-10 | +9.9% | legal | SEC EDGAR | CAPR 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-03-10 | +9.9% | news | Yahoo Finance | Assessing Capricor Therapeutics (CAPR) Valuation After A Strong Short Term Share Price Run - Yahoo Finance |
| 2026-03-10 | +9.9% | legal | Stock Titan | FDA resumes review of Duchenne drug Deramiocel, sets Aug. 22 deadline - Stock Titan |
| 2026-03-10 | +9.9% | legal | Benzinga | Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review - Benzinga |
| 2026-03-10 | +9.9% | legal | Seeking Alpha | Capricorgains FDA reviews rejected cell therapy (CAPR:NASDAQ) - Seeking Alpha |
| 2026-03-10 | +9.9% | news | Investing.com | H.C. Wainwright reiterates Buy on Capricor stock, $60 target - Investing.com |
| 2026-03-10 | +9.9% | legal | Investing.com | Capricor Therapeutics stock surges on FDA BLA review resumption - Investing.com |
| 2026-03-10 | +9.9% | legal | Investing.com | Jones Trading reiterates Capricor stock Buy on FDA review resumption - Investing.com |
| 2026-03-10 | +9.9% | legal | Investing.com Nigeria | Capricor Therapeutics stock surges on FDA BLA review resumption By Investing.com - Investing.com Nigeria |
| 2026-03-10 | +9.9% | legal | Stock Titan | FDA sets new Deramiocel PDUFA date for Capricor (NASDAQ: CAPR) - Stock Titan |
| 2026-04-13 | +9.1% | earnings | MarketBeat | Capricor Therapeutics (NASDAQ:CAPR) Shares Up 9.7% - Should You Buy? - MarketBeat |
| 2026-03-13 | -9.0% | analyst | MT Newswires | B. Riley Adjusts Price Target on Capricor Therapeutics to $63 From $50, Maintains Buy Rating |
| 2026-03-13 | -9.0% | earnings | GuruFocus.com | Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ... |
| 2026-03-13 | -9.0% | news | Seeking Alpha | Capricor Therapeutics, Inc. (CAPR) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow |
| 2026-03-13 | -9.0% | analyst | Seeking Alpha | Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel |
| 2026-03-13 | -9.0% | legal | Seeking Alpha | Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone |
| 2026-03-13 | -9.0% | earnings | Seeking Alpha | Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript |
| 2026-03-13 | -9.0% | earnings | Benzinga | Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates - Benzinga |
| 2026-03-13 | -9.0% | news | Stocktwits | CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - Stocktwits |
| 2026-03-13 | -9.0% | news | GuruFocus | Capricor Therapeutics (CAPR) Shares Recommended for Purchase Ami - GuruFocus |
| 2026-03-13 | -9.0% | earnings | Investing.com | Cantor Fitzgerald reiterates Capricor stock rating after earnings - Investing.com |
| 2026-01-05 | -9.0% | earnings | MarketBeat | Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat |
| 2026-03-07 | +8.9% | news | Trefis | Capricor Therapeutics Stock Pre-Market (+12%): 91-Day Insider Lock-Up Period Expires - Trefis |
| 2021-08-12 | -8.9% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2024-10-17 | -8.4% | legal | SEC EDGAR | CAPR 8-K: 1.01, 7.01 (SEC Filing) |
| 2026-04-10 | +8.4% | M&A | Stock Titan | Capricor Therapeutics (NASDAQ: CAPR) details 2026 meeting, board elections, pay and Deramiocel deals - Stock Titan |
| 2026-04-10 | +8.4% | legal | Stock Titan | [ARS] CAPRICOR THERAPEUTICS, INC. SEC Filing - Stock Titan |
| 2022-04-01 | +7.3% | legal | SEC EDGAR | CAPR 8-K: 8.01 (SEC Filing) |
| 2025-05-13 | +7.1% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2026-03-12 | -7.1% | earnings | Seeking Alpha | Capricor Therapeutics, Inc. GAAP EPS of -$0.62 misses by $0.08, revenue of $0M |
| 2026-03-12 | -7.1% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2026-03-12 | -7.1% | news | Stock Titan | Duchenne trial drug from Capricor slows key task decline 83% - Stock Titan |
| 2026-03-12 | -7.1% | news | Stock Titan | Cell therapy for Duchenne slows key eating task decline by 83% - Stock Titan |
| 2026-03-12 | -7.1% | news | simplywall.st | Is It Too Late To Consider Capricor Therapeutics (CAPR) After Strong Multi Year Share Gains? - simplywall.st |
| 2025-12-07 | +6.5% | analyst | Seeking Alpha | Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel |
| 2025-12-06 | +6.5% | news | Seeking Alpha | Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript |
| 2022-03-10 | -6.4% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2025-04-08 | -6.4% | legal | SEC EDGAR | CAPR 8-K: 5.02 (SEC Filing) |
| 2021-04-30 | -5.9% | legal | SEC EDGAR | CAPR 8-K: 1.01 and (SEC Filing) |
| 2021-06-21 | +5.7% | legal | SEC EDGAR | CAPR 8-K: 8.01 and (SEC Filing) |
| 2025-11-11 | +5.3% | legal | Seeking Alpha | Capricor signals pivotal HOPE-3 data imminent as FDA review process advances for deramiocel |
| 2025-11-11 | +5.3% | earnings | Seeking Alpha | Capricor Therapeutics, Inc. (CAPR) Q3 2025 Earnings Call Transcript |
| 2022-07-19 | +5.1% | legal | SEC EDGAR | CAPR 8-K: 8.01 and (SEC Filing) |
| 2026-03-25 | +5.0% | legal | TMX Newsfile | Caprock Intersects 38.48 g/t Au over 1.6m Included Within a Broader Interval of 2.84 g/t over 23.2m at Destiny |
| 2025-12-18 | +5.0% | legal | Seeking Alpha | Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript |
| 2025-12-18 | +5.0% | news | Yahoo Finance | Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory - Yahoo Finance |
| 2026-01-09 | -4.9% | news | The Motley Fool | Here's Why This Biotechnology Skyrocketed by 439% in December - The Motley Fool |
| 2023-09-06 | +4.9% | legal | SEC EDGAR | CAPR 8-K: 5.02 and (SEC Filing) |
| 2026-04-22 | -4.8% | news | GlobeNewswire | Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting |
| 2026-04-22 | -4.8% | news | Stock Titan | Duchenne trial data show slower loss of self-feeding ability - Stock Titan |
| 2026-04-22 | -4.8% | news | Stocktwits | CAPR Stock Draws Investor Attention After AAN Presentation For DMD Therapy - Stocktwits |
| 2026-04-22 | -4.8% | legal | Sahm | How Investors May Respond To Capricor Therapeutics (CAPR) HOPE-3 Data and Pending FDA Decision - Sahm |
| 2026-04-01 | +4.8% | news | Investing.com | Capricor Therapeutics director sells $3.5m in shares - Investing.com |
| 2026-04-01 | +4.8% | news | Stock Titan | Capricor (NASDAQ: CAPR) EVP sells 25K shares after option exercises - Stock Titan |
| 2026-04-01 | +4.8% | news | Investing.com | Capricor Therapeutics EVP Krasney sells $752k in shares - Investing.com |
| 2026-04-01 | +4.8% | news | Stock Titan | Director at Capricor (NASDAQ: CAPR) sells 115,000 shares via 10b5-1 plan - Stock Titan |
| 2026-04-01 | +4.8% | executive | Stock Titan | Capricor (NASDAQ: CAPR) CFO sells 25K shares after option exercise - Stock Titan |
| 2026-03-31 | +4.8% | earnings | MarketBeat | Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average - What's Next? - MarketBeat |
| 2026-03-31 | +4.8% | legal | Stock Titan | [144] CAPRICOR THERAPEUTICS, INC. SEC Filing - Stock Titan |
| 2025-08-12 | +4.7% | earnings | Seeking Alpha | Capricor Therapeutics, Inc. Q2 2025 Earnings Preview |
| 2025-08-12 | +4.7% | earnings | Seeking Alpha | Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Call Transcript |
| 2026-04-02 | +4.6% | legal | MT Newswires | Capricor Therapeutics Insider Sold Shares Worth $3,515,468, According to a Recent SEC Filing |
| 2026-04-02 | +4.6% | earnings | MarketBeat | Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock - MarketBeat |
| 2026-04-02 | +4.6% | earnings | MarketBeat | Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,667,397.05 in Stock - MarketBeat |
| 2026-04-02 | +4.6% | earnings | MarketBeat | Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.6% - Here's Why - MarketBeat |
| 2026-04-02 | +4.6% | legal | Stock Titan | CAPR SEC Filings - Capricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2026-04-02 | +4.6% | news | Stock Titan | Option exercise and 10b5-1 sales reported by CAPR (NASDAQ: CAPR) - Stock Titan |
| 2023-12-11 | +4.3% | legal | SEC EDGAR | CAPR 8-K: 8.01 and (SEC Filing) |
| 2024-02-29 | +4.2% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2022-05-10 | -4.1% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2026-02-20 | -4.1% | news | DirectorsTalk Interviews | Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Unveiling a 74% Potential Upside in the Biotech Arena - DirectorsTalk Interviews |
| 2021-05-13 | +4.0% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2021-11-09 | -3.5% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2023-07-24 | -3.1% | legal | SEC EDGAR | CAPR 8-K: 5.02 and (SEC Filing) |
| 2025-08-18 | -3.1% | earnings | Seeking Alpha | Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript |
| 2025-12-30 | -3.1% | earnings | MarketBeat | Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5% - Here's What Happened - MarketBeat |
| 2023-03-15 | -2.8% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2026-01-16 | +2.8% | analyst | Investing.com | Capricor Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com |
| 2025-10-31 | -2.8% | news | Stock Titan | Capricor (NASDAQ: CAPR) schedules financial results call for Nov 10 at 4:30 p.m. ET - Stock Titan |
| 2025-10-31 | -2.8% | news | Quiver Quantitative | Capricor Therapeutics to Announce Third Quarter 2025 Financial Results on November 10, 2025 - Quiver Quantitative |
| 2025-11-10 | +2.8% | earnings | Seeking Alpha | Capricor Therapeutics, Inc. GAAP EPS of -$0.54 beats by $0.01 |
| 2025-11-10 | +2.8% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2025-11-10 | +2.8% | earnings | Yahoo Finance | Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance |
| 2024-11-13 | +2.7% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2026-01-10 | +2.7% | news | Seeking Alpha | Capricor Therapeutics: A High Risk/High Reward Name |
| 2026-01-10 | +2.7% | news | Seeking Alpha | Capricor Therapeutics: A High Risk/High Reward Name - Seeking Alpha |
| 2025-05-27 | +2.4% | legal | SEC EDGAR | CAPR 8-K: 5.02 and 5.07 (SEC Filing) |
| 2024-08-07 | -2.4% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2024-05-13 | -2.4% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2026-03-17 | +2.2% | news | Yahoo Finance | Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance - Yahoo Finance |
| 2026-04-04 | -1.8% | news | simplywall.st | Capricor Therapeutics (CAPR) Valuation After New Deramiocel Data And Upcoming PDUFA Milestone - simplywall.st |
| 2026-04-04 | -1.8% | news | Stock Traders Daily | Precision Trading with Capricor Therapeutics Inc. (CAPR) Risk Zones - Stock Traders Daily |
| 2026-04-04 | -1.8% | news | Sahm | Capricor Therapeutics (CAPR) Valuation After New Deramiocel Data And Upcoming PDUFA Milestone - Sahm |
| 2026-04-03 | -1.8% | news | Stock Titan | Capricor Therapeutics (CAPR) director sells 7,529 exercised shares - Stock Titan |
| 2026-01-21 | -1.8% | legal | Yahoo Finance | Is FDA’s No-New-Trial Stance on Deramiocel Reshaping the Investment Case for Capricor Therapeutics (CAPR)? - Yahoo Finance |
| 2026-04-09 | -1.8% | earnings | MarketBeat | JPMorgan Chase & Co. Decreases Stock Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat |
| 2026-03-11 | +1.7% | earnings | Seeking Alpha | Capricor Therapeutics, Inc. Q4 2025 Earnings Preview |
| 2025-12-10 | -1.6% | news | Seeking Alpha | Capricor: A Detailed Examination Of Hope-3 |
| 2025-12-10 | -1.6% | analyst | Investing.com | Piper Sandler raises Capricor Therapeutics stock price target to $45 on trial success - Investing.com |
| 2025-12-10 | -1.6% | news | Seeking Alpha | Capricor: A Detailed Examination Of Hope-3 (NASDAQ:CAPR) - Seeking Alpha |
| 2026-03-18 | +1.6% | news | Insider Monkey | Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance |
| 2026-03-23 | -1.5% | M&A | TMX Newsfile | Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp. |
| 2026-04-15 | -1.4% | earnings | MarketBeat | Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Increases By 34.6% - MarketBeat |
| 2026-04-15 | -1.4% | earnings | MarketBeat | Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat |
| 2025-09-29 | +1.0% | news | Seeking Alpha | Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026 |
| 2025-09-29 | +1.0% | legal | Seeking Alpha | Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway |
| 2023-05-11 | -0.9% | legal | SEC EDGAR | CAPR 8-K: 2.02 and (SEC Filing) |
| 2026-03-14 | -0.8% | news | Simply Wall St. | Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? |
| 2026-03-14 | -0.8% | news | Yahoo Finance | Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge? - Yahoo Finance |
| 2026-01-20 | +0.7% | news | Yahoo Finance | Is Capricor Therapeutics (CAPR) Still Attractive After A 72% One Year Share Price Jump - Yahoo Finance |
| 2026-01-20 | +0.7% | legal | Yahoo Finance | Capricor Therapeutics (CAPR) Valuation After FDA Requests HOPE-3 Data For Deramiocel Regulatory Review - Yahoo Finance |
| 2026-01-20 | +0.7% | legal | Stock Titan | FDA asks for full HOPE-3 data on DMD cell therapy, no new trials - Stock Titan |
| 2023-07-13 | +0.6% | legal | SEC EDGAR | CAPR 8-K: 5.02 and (SEC Filing) |
| 2026-04-14 | -0.6% | legal | Stocktwits | CAPR Stock Gains Steam: Former Capricor Exec Could Become FDA’s Top Gene Therapy Regulator Ahead Of High-Stakes DMD Decision - Stocktwits |
| 2021-07-27 | +0.5% | legal | SEC EDGAR | CAPR 8-K: 5.02 and (SEC Filing) |
| 2026-04-23 | +0.4% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | CAPR (Capricor Therapeutics Inc.) reports wider than expected Q4 2025 loss, stock notches small gain in daily trading. - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-23 | +0.4% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | CAPR (Capricor Therapeutics Inc.) reports wider Q4 2025 loss than estimates, shares dip 1.28% in today's trading. - Expert Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-23 | +0.4% | earnings | Xã Thanh Hà | CAPR (Capricor Therapeutics Inc.) reports wider than expected Q4 2025 loss, stock notches small gain in daily trading. - Xã Thanh Hà |
| 2026-02-24 | +0.1% | news | Stock Titan | Duchenne trial to showcase Deramiocel Phase 3 data at 2026 MDA meeting - Stock Titan |
| 2026-04-26 | — | legal | MSN | CAPR stock gains steam: Former Capricor exec could become FDA’s top gene therapy regulator ahead of high-stakes DMD decision - MSN |
| 2026-04-26 | — | news | MSN | CAPR stock draws investor attention after AAN presentation for DMD therapy - MSN |
| 2026-04-25 | — | news | simplywall.st | Assessing Capricor Therapeutics (CAPR) Valuation After HOPE-3 Phase 3 Data And BLA Review Progress - simplywall.st |
| 2026-04-24 | — | news | Simply Wall St. | How Phase 3 HOPE-3 DMD Data And BLA Review At Capricor Therapeutics (CAPR) Has Changed Its Investment Story |
| 2026-04-24 | — | news | Simply Wall St. | We're Not Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn |
| 2026-04-24 | — | news | Yahoo Finance | We're Not Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn - Yahoo Finance |
| 2026-04-24 | — | news | MSN | Roth Capital Maintains Capricor Therapeutics (CAPR) Buy Recommendation - MSN |